Plasma amantadine concentrations in patients with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue 5, 2009, Pages 351-353

  Nishikawa, N ^a   Nagai, M ^a   Moritoyo, T ^a   Yabe, H ^a   Nomoto, M ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amantadine; Creatinine clearance; Parkinson's disease; Plasma concentration; Renal function; Side effects

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; CREATININE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELIRIUM; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HALLUCINATION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MYOCLONUS; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; AMANTADINE; ANTIPARKINSON AGENTS; CREATININE; DELIRIUM; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; MYOCLONUS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 67349274671     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.08.005     Document Type: Article

References (16)

1. Deleu D., Northway M.G., and Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharm 41 (2002) 261-309
2. Parfitt K., Sweetman S.C., Blake P.S., and Parsons A.V. Amantadine hydrochloride. Martindale: the complete drug reference. 32nd ed. (1999), Pharmaceutical Press, London 1129-1130
3. Hayden F.G. Antimicrobial agents: antiviral agents. In: Hardman J.G. (Ed). Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. (1996), MacGraw-Hill, New York 1209-1211
4. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., and Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 (1998) 1323-1326
5. Wu M.J., Ing T.S., Soung L.S., Daugirdas J.T., Hano J.E., and Gandhi V.C. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 17 (1982) 19-23
6. Stumph M.J., Noall M.W., and Knight V. Gas-chromatographic determination of amantadine in human urine. Clin Chem 26 (1980) 295-296
7. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 15 (1976) 31-41
8. Macchio G.J., Ito V., and Sahgal V. Amantadine-induced coma. Arch Phys Med Rehabil 74 (1993) 1119-1120
9. Ing T.S., Daugirdas J.T., Soung L.S., Klawans H.L., Mahurkar S.D., Hayashi J.A., et al. Toxic effects of amantadine in patients with renal failure. Can Med Assoc J 120 (1979) 695-698
10. Matsunaga K., Uozumi T., Qingrui L., Hashimoto T., and Tsuji S. Amantadine-induced cortical myoclonus. Neurology 56 (2001) 279-280
11. Pfeiffer R.F. Amantadine-induced "vocal" myoclonus. Mov Disord 11 (1996) 104-106
12. Kornhuber J., Bormann J., Hübers M., Rusche K., and Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206 (1991) 297-300
13. Kim H.S., Park I.S., Lim H.K., Choi H.S., Oh S., Park W.K., et al. N-Methyl-d-aspartate receptor antagonists enhance the head-twitch response, a 5-hydroxytryptamine2 receptor-mediated behaviour, in reserpine-treated mice. J Pharm Pharmacol 52 (2000) 717-722
14. Nomoto M., Nagai M., Nakatsuka A., Nishikawa N., Yabe H., Moritoyo H., et al. Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease. J Neurol 253 Suppl. 3 (2006) iii53-i59
15. Aoki F.Y., and Sitar D.S. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharm 14 (1988) 35-51
16. Horadam V.W., Sharp J.G., Smilack J.D., McAnalley B.H., Garriott J.C., Stephens M.K., et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 94 (1981) 454-458